PMID- 29730395
OWN - NLM
STAT- MEDLINE
DCOM- 20190715
LR  - 20190715
IS  - 1090-2139 (Electronic)
IS  - 0889-1591 (Linking)
VI  - 71
DP  - 2018 Jul
TI  - Profiling inflammatory signatures of schizophrenia: A cross-sectional and 
      meta-analysis study.
PG  - 28-36
LID - S0889-1591(18)30173-9 [pii]
LID - 10.1016/j.bbi.2018.05.002 [doi]
AB  - We aimed to profile a broad panel of inflammatory markers in patients with 
      schizophrenia and healthy controls. Additionally, we performed a meta-analysis of 
      chemokine alterations that have not been subjected to quantitative synthesis so 
      far. We recruited 78 patients with schizophrenia and 78 healthy controls, and 
      measured inflammatory markers using the Luminex technology. After adjustment for 
      multiple testing, we found elevated levels of interleukin (IL)-1 receptor 
      antagonist (IL-1RA), IL-6, IL-7, IL-8, IL-9, IL-10, IL-13, interferon-gamma, 
      eotaxin-1, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte 
      chemoattractant protein-1 (MCP-1), platelet-derived growth factor with two B 
      subunits (PDGF-BB), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, vascular 
      endothelial growth factor A (VEGF-A) and RANTES in multiple-episode schizophrenia 
      (MES) patients. These differences, except for the difference in eotaxin-1 levels, 
      appeared to be significant after co-varying for the dosage of antipsychotics. 
      There were no significant differences in the levels of immune markers between 
      first-episode schizophrenia (FES) patients and controls. Our meta-analysis 
      revealed elevated levels of MCP-1 in first-episode psychosis (FEP) patients and 
      MES individuals. Other chemokine alterations (elevated levels of IL-8, eotaxin-1 
      and MIP-1beta) were present only in MES patients. Our results indicate that 
      dysregulation of immune response in schizophrenia develops with illness 
      progression or appears as a long-term medication effect. Chemokine alterations 
      are another example of aberrant immune response in schizophrenia patients. 
      Elevated levels of MCP-1 might represent trait markers since these alterations 
      were found in FEP and MES patients. Other chemokine alterations might be the 
      markers of disease progression or might represent medication effects.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Frydecka, Dorota
AU  - Frydecka D
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Krzystek-Korpacka, Malgorzata
AU  - Krzystek-Korpacka M
AD  - Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10 
      Street, 50-368 Wroclaw, Poland.
FAU - Lubeiro, Alba
AU  - Lubeiro A
AD  - Department of Psychiatry, School of Medicine, University of Valladolid, Av. Ramon 
      y Cajal, 7, 47005 Valladolid, Spain.
FAU - Stramecki, Filip
AU  - Stramecki F
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Stanczykiewicz, Bartlomiej
AU  - Stanczykiewicz B
AD  - Department of Nervous System Diseases, Wroclaw Medical University, Bartla 5 
      Street, 51-618 Wroclaw, Poland.
FAU - Beszlej, Jan Aleksander
AU  - Beszlej JA
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Piotrowski, Patryk
AU  - Piotrowski P
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Kotowicz, Kamila
AU  - Kotowicz K
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Szewczuk-Boguslawska, Monika
AU  - Szewczuk-Boguslawska M
AD  - Department of Psychiatry, Wroclaw Medical University, Pasteura 10 Street, 50-367 
      Wroclaw, Poland.
FAU - Pawlak-Adamska, Edyta
AU  - Pawlak-Adamska E
AD  - Department of Experimental Therapy, Laboratory of Immunopathology, Institute of 
      Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12 
      Street, 51-114 Wroclaw, Poland.
FAU - Misiak, Blazej
AU  - Misiak B
AD  - Department of Genetics, Wroclaw Medical University, Marcinkowskiego 1 Street, 
      50-368 Wroclaw, Poland. Electronic address: blazej_misiak@interia.pl.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20180503
PL  - Netherlands
TA  - Brain Behav Immun
JT  - Brain, behavior, and immunity
JID - 8800478
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Interleukins)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Chemokine CCL2/metabolism/physiology
MH  - Chemokines/immunology/*metabolism
MH  - Cross-Sectional Studies
MH  - Cytokines/immunology/*metabolism
MH  - Female
MH  - Humans
MH  - Inflammation/metabolism/physiopathology
MH  - Intercellular Signaling Peptides and Proteins/immunology/metabolism
MH  - Interleukins/immunology/*metabolism
MH  - Male
MH  - Schizophrenia/genetics/*immunology
OTO - NOTNLM
OT  - Chemokines
OT  - Immunity
OT  - Inflammation
OT  - Peripheral markers
OT  - Psychosis
EDAT- 2018/05/08 06:00
MHDA- 2019/07/16 06:00
CRDT- 2018/05/07 06:00
PHST- 2017/12/12 00:00 [received]
PHST- 2018/04/27 00:00 [revised]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2019/07/16 06:00 [medline]
PHST- 2018/05/07 06:00 [entrez]
AID - S0889-1591(18)30173-9 [pii]
AID - 10.1016/j.bbi.2018.05.002 [doi]
PST - ppublish
SO  - Brain Behav Immun. 2018 Jul;71:28-36. doi: 10.1016/j.bbi.2018.05.002. Epub 2018 
      May 3.